Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
ADNOC Gas Targets Up to $4B Profit in 2026 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Airbus Joins Air India A320 Altitude Drop Probe 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its blockbuster obesity drug, Wegovy. The Danish pharmaceutical giant projects local currency sales growth between 16% and 24%, down from 26% in 2024 but aligning with analysts' expectations of around 20%.
Novo Nordisk faces increasing competition from Eli Lilly (NYSE:LLY), a key rival in the weight-loss drug market. Despite this, the company reported strong fourth-quarter results, with operating profit surging 37% to 36.7 billion Danish crowns ($5.12 billion), surpassing analysts' estimates of 33.6 billion. For 2025, the company expects operating profit growth between 19% and 27%, compared to last year's 26%.
Wegovy sales more than doubled in Q4, reaching 19.9 billion crowns, up from 9.6 billion a year earlier and exceeding the 17.3 billion recorded in Q3. The sustained demand underscores the drug’s strong market position, although future growth is expected to decelerate.
As the weight-loss drug market evolves, Novo Nordisk continues to navigate supply constraints and rising competition. Investors remain focused on the company’s long-term outlook as it balances expansion efforts with growing market challenges.
